{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:10:20Z","timestamp":1793257820489,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"5","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies for which graft-versus-host disease (GVHD) remains a major complication. The use of donor T-regulatory cells (Tregs) to prevent GVHD appears promising, including in our previous evaluation of an engineered graft product (T-reg graft) consisting of the timed, sequential infusion of CD34+ hematopoietic stem cells and high-purity Tregs followed by conventional T cells. However, whether immunosuppressive prophylaxis can be removed from this protocol remains unclear. We report the results of the first stage of an open-label single-center phase 2 study (NCT01660607) investigating T-reg graft in myeloablative HCT of HLA-matched and 9\/10-matched recipients. Twenty-four patients were randomized to receive T-reg graft alone (n\u00a0= 12) or T-reg graft plus single-agent GVHD prophylaxis (n\u00a0= 12) to determine whether T-reg graft alone was noninferior in preventing acute GVHD. All patients developed full-donor myeloid chimerism. Patients with T-reg graft alone vs with prophylaxis had incidences of grade 3 to 4 acute GVHD of 58% vs 8% (P\u00a0= .005) and grade 3 to 4 of 17% vs 0% (P\u00a0= .149), respectively. The incidence of moderate-to-severe chronic GVHD was 28% in the T-reg graft alone arm vs 0% with prophylaxis (P\u00a0= .056). Among patients with T-reg graft and prophylaxis, CD4+ T-cell\u2013to\u2013Treg ratios were reduced after transplantation, gene expression profiles showed reduced CD4+ proliferation, and the achievement of full-donor T-cell chimerism was delayed. This study indicates that T-reg graft with single-agent tacrolimus is preferred over T-reg graft alone for the prevention of acute GVHD. This trial was registered at www.clinicaltrials.gov as #NCT01660607.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011625","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T21:23:15Z","timestamp":1702502595000},"page":"1105-1115","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":39,"title":["Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3544-0113","authenticated-orcid":false,"given":"Cameron S.","family":"Bader","sequence":"first","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5533-5700","authenticated-orcid":false,"given":"Anna","family":"Pavlova","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"},{"name":"2Cellular Immune Tolerance Program, Stanford Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori S.","family":"Muffly","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-4172","authenticated-orcid":false,"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"},{"name":"2Cellular Immune Tolerance Program, Stanford Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Johnston","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"},{"name":"2Cellular Immune Tolerance Program, Stanford Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-2366","authenticated-orcid":false,"given":"John S.","family":"Tamaresis","sequence":"additional","affiliation":[{"name":"3Biomedical Data Sciences, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Agrawal","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Hematopoietic Stem Cell Transplantation, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9918-9653","authenticated-orcid":false,"given":"Nathaniel B.","family":"Fernhoff","sequence":"additional","affiliation":[{"name":"5Orca Biosystems, Inc, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Putnam","sequence":"additional","affiliation":[{"name":"5Orca Biosystems, Inc, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Killian","sequence":"additional","affiliation":[{"name":"5Orca Biosystems, Inc, Menlo Park, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8625-5981","authenticated-orcid":false,"given":"Bryan J.","family":"Xie","sequence":"additional","affiliation":[{"name":"63T Biosciences, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"},{"name":"2Cellular Immune Tolerance Program, Stanford Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett H.","family":"Meyer","sequence":"additional","affiliation":[{"name":"1Stanford Blood and Marrow Transplantation and Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA"},{"name":"2Cellular Immune Tolerance Program, Stanford Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"issue":"22","key":"2024031115401679400_bib1","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024031115401679400_bib2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2024031115401679400_bib3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024031115401679400_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/bmt.2015.222","article-title":"A\u00a0randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation","volume":"51","author":"Kanda","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024031115401679400_bib5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"2024031115401679400_bib6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"2024031115401679400_bib7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"issue":"10","key":"2024031115401679400_bib8","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V99.10.3493","article-title":"The infusion of ex\u00a0vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality","volume":"99","author":"Taylor","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2024031115401679400_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.20020399","article-title":"Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation","volume":"196","author":"Hoffmann","year":"2002","journal-title":"J\u00a0Exp Med"},{"issue":"4","key":"2024031115401679400_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/bbmt.2003.50027","article-title":"Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425\u00a0T cells to allow an effective graft-versus-leukemia response","volume":"9","author":"Jones","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024031115401679400_bib11","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.beha.2011.05.005","article-title":"Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation","volume":"24","author":"Di Ianni","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"8","key":"2024031115401679400_bib12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"issue":"86","key":"2024031115401679400_bib13","doi-asserted-by":"crossref","first-page":"35611","DOI":"10.18632\/oncotarget.26242","article-title":"Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution","volume":"9","author":"Kellner","year":"2018","journal-title":"Oncotarget"},{"issue":"14","key":"2024031115401679400_bib14","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2024031115401679400_bib15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41375-023-01932-x","article-title":"A\u00a0pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect","volume":"37","author":"Guardalupi","year":"2023","journal-title":"Leukemia"},{"issue":"4","key":"2024031115401679400_bib16","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2024031115401679400_bib17","doi-asserted-by":"crossref","first-page":"e127244","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"2024031115401679400_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.bmt.1701131","article-title":"T\u00a0cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect","volume":"21","author":"Barrett","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024031115401679400_bib19","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.bbmt.2006.08.034","article-title":"T-cell depleted peripheral blood stem cell allotransplantation with T-cell add-back for patients with hematological malignancies: effect of chronic GVHD on outcome","volume":"12","author":"Montero","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024031115401679400_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"12","key":"2024031115401679400_bib21","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"issue":"5","key":"2024031115401679400_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pst.1813","article-title":"Equal-tailed confidence intervals for comparison of rates","volume":"16","author":"Laud","year":"2017","journal-title":"Pharm Stat"},{"issue":"8","key":"2024031115401679400_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"5","key":"2024031115401679400_bib24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"12","key":"2024031115401679400_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"2","key":"2024031115401679400_bib26","first-page":"275","article-title":"False discovery rates: a new deal","volume":"18","author":"Stephens","year":"2017","journal-title":"Biostatistics"},{"issue":"13","key":"2024031115401679400_bib27","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"12","key":"2024031115401679400_bib28","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1101\/gr.192237.115","article-title":"Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells","volume":"25","author":"Kowalczyk","year":"2015","journal-title":"Genome Res"},{"issue":"6","key":"2024031115401679400_bib29","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"6","key":"2024031115401679400_bib30","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2019001208","article-title":"Regulatory T cells promote alloengraftment in a model of late-gestation in utero hematopoietic cell transplantation","volume":"4","author":"Riley","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2024031115401679400_bib31","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2004-08-3213","article-title":"Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation","volume":"105","author":"Hanash","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2024031115401679400_bib32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1399-3062.2007.00235.x","article-title":"Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Almyroudis","year":"2007","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"2024031115401679400_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007890-199902270-00022","article-title":"Ex\u00a0vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect","volume":"67","author":"Novitzky","year":"1999","journal-title":"Transplantation"},{"issue":"1","key":"2024031115401679400_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024031115401679400_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbmt.2017.02.013","article-title":"Marked in\u00a0vivo donor regulatory T cell expansion via interleukin-2 and TL1a-Ig stimulation ameliorates graft-versus-host disease but preserves graft-versus-leukemia in recipients after hematopoietic stem cell transplantation","volume":"23","author":"Wolf","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024031115401679400_bib36","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.3389\/fimmu.2019.01624","article-title":"Activation of the DR3-TL1A axis in donor mice leads to regulatory T cell expansion and activation with reduction in graft-versus-host disease","volume":"10","author":"Mavers","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"2024031115401679400_bib37","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.4049\/jimmunol.1102376","article-title":"Constitutive nuclear localization of NFAT in Foxp3+ regulatory T cells independent of calcineurin activity","volume":"188","author":"Li","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"40","key":"2024031115401679400_bib38","doi-asserted-by":"crossref","first-page":"16258","DOI":"10.1073\/pnas.1203870109","article-title":"Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells","volume":"109","author":"Vaeth","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2024031115401679400_bib39","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2008-07-169342","article-title":"Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation","volume":"112","author":"Cutler","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2024031115401679400_bib40","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"2024031115401679400_bib41","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2024031115401679400_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/labinvest.2009.3","article-title":"Both tacrolimus and sirolimus decrease Th1\/Th2 ratio, and increase regulatory T lymphocytes in the liver after ischemia\/reperfusion","volume":"89","author":"Arias-Diaz","year":"2009","journal-title":"Lab Invest"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1105\/2217602\/blooda_adv-2023-011625-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/5\/1105\/2217602\/blooda_adv-2023-011625-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T15:41:33Z","timestamp":1710171693000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/5\/1105\/506611\/Single-center-randomized-trial-of-T-reg-graft"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011625","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]}}}